Although the stock market was having a generally strong week, that isn't the case for vaccine technology company Moderna (NASDAQ:MRNA). The company, which was a leader in developing one of the initial COVID-19 vaccines, has plunged by 20% for the week as of mid-day Thursday.
Disappointing sales guidance is the key reason for the plunge
The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin. The prior forecast called for $2.5 billion to $3.5 billion in sales for 2025, but the updated guidance calls for $1.5 billion to $2.5 billion. At the midpoint, that represents a $1 billion reduction, or 50% lower revenue.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. See the 10 stocks »
Moderna had previously said that it will be break even on operating cash flow by 2028, which had already been pushed back. Now investors aren't so sure.
Not only is COVID-19 vaccine demand weaker than expected, but its market share has declined. The company had 48% of COVID vaccine demand in 2023, compared with just 40% this year. Not only that, but Novavax's vaccine product is set to hit the market soon, which could further erode Moderna's share.
There are some good reasons to have a positive outlook
It isn't all bad news when it comes to Moderna. For one thing, the company still has $6.9 billion in cash and short-term investments on its balance sheet (the entire market cap is just $13 billion) and is taking steps to reduce costs for the time being.
In addition, the company has 10 new products in its pipeline that it hopes will receive FDA approval within the next three years (including a trio that could be approved in 2025 alone). One example is the combination flu and COVID shot it has been developing. In a nutshell, Moderna has plenty of runway, and if the company can get its promising candidates to market, it could still have a bright future. But it is important to know that it is a big if.
Don’t miss this second chance at a potentially lucrative opportunity
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
- Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $353,272!*
- Apple: if you invested $1,000 when we doubled down in 2008, you’d have $45,049!*
- Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $457,459!*
Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.
*Stock Advisor returns as of January 13, 2025
Matt Frankel has no position in any of the stocks mentioned. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy.
/Technology%20abstract%20by%20TU%20IS%20via%20iStock.jpg)
